Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Fosun Pharma’s $600 Million Hong Kong IPO: Is it a Steal?

publication date: Oct 12, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Fosun Pharmaceutical’s $600 million Hong Kong IPO is being marketed to potential investors as a value play, a way of investing in a large portfolio of China pharma companies at a discount. Here’s the pitch: Fosun owns 32% of China’s largest drug distributor, Sinopharm, a stake that is worth $2.6 billion. That equals 80% of Fosun’s total market capitalization – currently $3.3 billion. For a relatively small $600 million in value over and above Sinopharm, investors get Fosun’s drug production business and its stakes in a variety of China pharma companies. That, say the investment bankers, means investors are getting a discounted deal. More details....

Stock Symbols: (SHA 600196) (HK: 1099)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...



Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China

>>More events...
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Partners